Coronavirus Update: Novartis Joins Vaccine Efforts With Gene Therapy Approach
Plus: Oxford BioMedica, And Rehab Needs Of COVID-19 Survivors
Executive Summary
Having kept out of the race to develop a vaccine until now, Novartis has joined efforts with a collaboration using the AAV gene therapy vector.
You may also be interested in...
Novartis Steps Up To Plate To Produce Pfizer/BioNTech COVID-19 Vaccine
In the latest example of cross-industry collaboration in these turbulent times, Novartis is joining forces with Pfizer and BioNTech to help produce their in-demand mRNA vaccine at a facility in Switzerland.
Sandoz Unveils Zero-Profit COVID-19 Portfolio
Lutz Hegemann, chief operating officer for global health at Novartis, says the project will continue until a vaccine or curative treatments have reached the world's poorest places, not just until they are first approved in a high income country.
Novartis Unveils Zero Profit COVID-19 Drugs Portfolio
Lutz Hegemann, chief operating officer for global health at Novartis, tells Scrip the project will continue until a vaccine or curative treatments have reached the world's poorest places, not just until they are first approved in a high income country.